Allogeneic Donor-Derived Anti-CD19 CAR T Cell Is a Promising Therapy for Relapsed/Refractory B-ALL After Allogeneic Hematopoietic Stem-Cell Transplantation
| Autor: | Xiebing Bao, Lili Zhou, Miao Miao, Yue Han, Weiqing Qian, Huiying Qiu, Jingsheng Hua, Jian Zhang, Caixia Li, Zhengzheng Fu, Depei Wu, Xiaoxia Wu |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
Adult
Male Oncology Cancer Research medicine.medical_specialty Transplantation Conditioning Adolescent T-Lymphocytes medicine.medical_treatment Hematopoietic stem cell transplantation CD19 Young Adult 03 medical and health sciences 0302 clinical medicine Refractory hemic and lymphatic diseases Internal medicine medicine Humans Transplantation Homologous Prospective Studies Child Prospective cohort study Receptors Chimeric Antigen biology business.industry Hematopoietic Stem Cell Transplantation Hematology Precursor Cell Lymphoblastic Leukemia-Lymphoma medicine.disease Chimeric antigen receptor Transplantation Haematopoiesis Cytokine release syndrome 030220 oncology & carcinogenesis biology.protein Female business 030215 immunology |
| Zdroj: | Clinical Lymphoma Myeloma and Leukemia. 20:610-616 |
| ISSN: | 2152-2650 |
| DOI: | 10.1016/j.clml.2020.04.007 |
| Popis: | Introduction Currently, effective and safe salvage therapies are limited among patients with relapsed acute lymphoblastic leukemia after allogeneic hematopoietic stem-cell transplantation (allo-HSCT). Anti-CD19 chimeric antigen receptor T (CAR T) cell is a promising treatment. Patients and Methods We studied 11 patients with B-cell acute lymphoblastic leukemia that relapsed after allo-HSCT between September 2017 and October 2019. Patients were treated with a dose of single-infusion donor-derived anti-CD19 CAR T cells. Results Eight patients (72.7%) experienced morphologic remissions. Seven (63.6%) experienced minimal residual disease–negative remission. The ongoing complete remission (CR) duration of 2 patients reached 22 months. The median overall survival was 9 months (range, 2-22 months). Only one patient with grade 1 acute graft-versus-host disease was observed. Two patients (18.2%) developed grade 3/4 cytokine release syndrome. Conclusion This prospective study showed allogeneic donor-derived anti-CD19 CAR T-cell therapy is an effective and safe salvage regimen for patients with relapsed/refractory B-cell acute lymphoblastic leukemia after allo-HSCT. Further randomized and multicenter investigations are needed to evaluate their potential role in relapsed acute lymphoblastic leukemia therapies after allo-HSCT. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect